Focal Therapy of Prostate Cancer by Radiofrequency and Photodynamic Therapy

2013 ◽  
pp. 727-751
Author(s):  
Bob Djavan ◽  
Herbert Lepor ◽  
Reza Zare ◽  
Seyed Saeid Dianat
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Focal Therapy

scholarly journals Focal Treatment of Prostate Cancer with Vascular-Targeted Photodynamic Therapy

2008 ◽  
Vol 8 ◽  
pp. 963-973 ◽  
Author(s):  
Scott E. Eggener ◽  
Jonathan A. Coleman
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Focal Therapy ◽  
Attractive Alternative ◽  
Screening Programs ◽  
Sexual Side Effects ◽  
Pathologic Features ◽  
Focal Treatment ◽  
Risk Of Progression ◽  
Targeted Photodynamic Therapy

Epidemiologic and pathologic features of prostate cancer have given rise to an interest in focal treatment for carefully selected patients. Prostate cancer remains highly prevalent, particularly in the U.S. and Europe. As screening programs have become more aggressive and widespread, a substantial proportion of men diagnosed with localized prostate cancer have disease characteristics associated with a low risk of progression. Treatments such as radical prostatectomy and radiation therapy can lead to durable recurrence-free survival in most patients, but carry variable risks of bowel, urinary, and sexual side effects. Few men and few urologists are comfortable leaving a potentially curable prostate cancer untreated. Focal therapy offers an attractive alternative for the patient faced with a choice between aggressive local intervention (radiation or surgery) and watchful waiting. Contemporary diagnostic biopsy strategies and imaging tools, and the development of predictive statistical models (nomograms), have led to improvements in tumor characterization and risk stratification, making focal therapy a viable treatment option for specific men. This article reviews the rationale and indications for focal therapy and highlights vascular-targeted photodynamic therapy (PDT) as one of many promising focal therapy techniques.

scholarly journals Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer

2021 ◽  
Author(s):  
Hanna T. Sjoberg ◽  
Yiannis Philippou ◽  
Anette L. Magnussen ◽  
Iain D. C. Tullis ◽  
Esther Bridges ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Vascular Function ◽  
Multimodality Treatment ◽  
Focal Therapy ◽  
Tumour Microenvironment ◽  
Fractionated Radiotherapy ◽  
Tumour Control ◽  
Early Phase Clinical Trials ◽  
Targeted Photodynamic Therapy

Abstract Background There is a need to improve the treatment of prostate cancer (PCa) and reduce treatment side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy for low-risk low-volume localised PCa, which rapidly disrupts targeted tumour vessels. There is interest in expanding the use of VTP to higher-risk disease. Tumour vasculature is characterised by vessel immaturity, increased permeability, aberrant branching and inefficient flow. FRT alters the tumour microenvironment and promotes transient ‘vascular normalisation’. We hypothesised that multimodality therapy combining fractionated radiotherapy (FRT) and VTP could improve PCa tumour control compared against monotherapy with FRT or VTP. Methods We investigated whether sequential delivery of FRT followed by VTP 7 days later improves flank TRAMP-C1 PCa tumour allograft control compared to monotherapy with FRT or VTP. Results FRT induced ‘vascular normalisation’ changes in PCa flank tumour allografts, improving vascular function as demonstrated using dynamic contrast-enhanced magnetic resonance imaging. FRT followed by VTP significantly delayed tumour growth in flank PCa allograft pre-clinical models, compared with monotherapy with FRT or VTP, and improved overall survival. Conclusion Combining FRT and VTP may be a promising multimodal approach in PCa therapy. This provides proof-of-concept for this multimodality treatment to inform early phase clinical trials.

scholarly journals Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project

2015 ◽  
Vol 33 (10) ◽  
pp. 1503-1509 ◽  
Author(s):  
B. G. Muller ◽  
W. van den Bos ◽  
M. Brausi ◽  
J. J. Fütterer ◽  
S. Ghai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Focal Therapy ◽  
Delphi Consensus

scholarly journals Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu Wang ◽  
Al Christopher De Leon ◽  
Reshani Perera ◽  
Eric Abenojar ◽  
Ramamurthy Gopalakrishnan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ultrasound Imaging ◽  
Prostate Gland ◽  
Ultrasound Contrast Agent ◽  
Tumor Model ◽  
Focal Therapy ◽  
Ultrasound Contrast Agents ◽  
Time Intensity Curve ◽  
Ultrasound Contrast

AbstractUltrasound imaging is routinely used to guide prostate biopsies, yet delineation of tumors within the prostate gland is extremely challenging, even with microbubble (MB) contrast. A more effective ultrasound protocol is needed that can effectively localize malignancies for targeted biopsy or aid in patient selection and treatment planning for organ-sparing focal therapy. This study focused on evaluating the application of a novel nanobubble ultrasound contrast agent targeted to the prostate specific membrane antigen (PSMA-targeted NBs) in ultrasound imaging of prostate cancer (PCa) in vivo using a clinically relevant orthotopic tumor model in nude mice. Our results demonstrated that PSMA-targeted NBs had increased extravasation and retention in PSMA-expressing orthotopic mouse tumors. These processes are reflected in significantly different time intensity curve (TIC) and several kinetic parameters for targeted versus non-targeted NBs or LUMASON MBs. These, may in turn, lead to improved image-based detection and diagnosis of PCa in the future.

Sign in / Sign up

Export Citation Format

Share Document